SBI Pharmaceuticals Co., Ltd.

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in the United States of America on the External Preparation for Skin containing 5-ALA.

U. S. Patent number: US 9,351,949 B2
Title of invention : Prophylactic/ Therapeutic Agent for Influenza Virus Infection
Assignees : SBI Pharmaceuticals Co., Ltd. Tokushima University
Filing date: June 3 , 2013

The corresponding patent was registered in Japan as of April 22, 2016 (Please refer to our news
release dated May 18, 2016.)

We have found that the formulation containing 5-ALA vitalized the epidermal cells and corneums to prevent and ameliorate skin roughness, dry skin, wrinkles, sagging skin and flecks and atopic dermatitis. This has resulted in the registration of the above-mentioned patent. The corresponding patent was registered in Japan in July 2007.

SBI Pharmaceuticals will continue to pursue various potential applications of 5-ALA, and focus on research and development to enrich the living of as many people as possible around the world.

*: 5-aminolevulinic acid (5-ALA)
An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

******************************************************************************************
For further information, please contact:
SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81-3-6229-0095

Please download PDF File